Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
2seventy bio, Inc. - Common Stock
(NQ:
TSVT
)
4.630
-0.180 (-3.74%)
Streaming Delayed Price
Updated: 3:29 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 2seventy bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
March 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
Earnings Scheduled For March 5, 2024
March 05, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
Via
Benzinga
A Preview Of 2seventy bio's Earnings
March 04, 2024
Via
Benzinga
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
March 01, 2024
From
2seventy bio, Inc.
Via
Business Wire
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
2seventy bio to Participate in Upcoming Investor Conferences
February 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio: Q3 Earnings Insights
November 14, 2023
Via
Benzinga
Preview: 2seventy bio's Earnings
November 13, 2023
Via
Benzinga
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
February 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
February 02, 2024
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 31, 2024
Via
Benzinga
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 31, 2024
Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on...
Via
Benzinga
Crude Oil Down 2%; Alphabet Shares Fall After Q4 Results
January 31, 2024
U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite falling more than 200 points on Wednesday. The Dow traded up 0.08% to 38,497.13 while the NASDAQ fell 1.41% to...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 30, 2024
Via
Benzinga
2seventy bio Announces New Strategic Path Forward
January 30, 2024
From
2seventy bio, Inc.
Via
Business Wire
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
January 07, 2024
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...
Via
Talk Markets
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
December 19, 2023
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &...
Via
Benzinga
Topics
ETFs
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
December 11, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
December 06, 2023
From
2seventy bio, Inc.
Via
Business Wire
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Tuesday, the FDA said it received reports of patients developing T-cell malig
Via
Benzinga
Exposures
Product Safety
Why Is Pharma Giant Bristol-Myers Squibb Stock Trading Lower Today?
November 20, 2023
Shares of Bristol-Myers Squibb Company (NYSE: BMY) and 2seventy Bio Inc (NASDAQ: TSVT) fell after the companies' efforts to win expanded U.S.
Via
Benzinga
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
November 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 20, 2023
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates...
Via
Benzinga
3 Biotech Stocks With Key Catalysts Coming in December
November 15, 2023
Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner.
Via
InvestorPlace
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
November 14, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
November 10, 2023
From
2seventy bio, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
October 26, 2023
Via
Benzinga
2 Growth Stocks That Could Rocket Higher Before the End of 2023
October 08, 2023
Potential approvals of new medicines expected soon could push these stocks through the roof.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023
October 12, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.